Inclusion on the list of medicines refundable by National Health insurance (B/28) and approved for hospital use (B/28 and B/50).
-
Clinical Benefit
Moderate
In dual therapy, in combination with a sulfonylurea the actual benefit of the proprietary medicinal product XELEVIA at a dose of 50 mg is moderate.
Low
In monotherapy the actual benefit of the proprietary medicinal products XELEVIA 25 mg and 50 mg is low.
Insufficient
In the indications in combination with metfomin the actual benefit of the proprietary medicinal products XELEVIA at dosages of 25 mg and 50 mg in their indications in combination with metformin, in dual therapy and triple therapy, is insufficient to justify reimbursement by National Health insurance.
Clinical Added Value
no clinical added value
In view of the available data, the Transparency Committee considers that the proprietary medicinal products XELEVIA at dosages of 25 mg and 50 mg of sitagliptin, in monotherapy or in dual therapy in combination with a sulfonylurea or insulin, offer no improvement in actual benefit (IAB V) in the treatment of diabetic patients with renal impairment.
Listen
